scholarly journals Adenoid Cystic Carcinoma of the Submandibular Gland, Locoregional Recurrence, and a Solitary Liver Metastasis More Than 30 Years Since Primary Diagnosis

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
A. Coupland ◽  
A. Sewpaul ◽  
A. Darne ◽  
S. White
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Distant Metastases ◽  
Primary Diagnosis ◽  
High Rate ◽  
Treatment Modalities ◽  
Rare Tumour ◽  
Salivary Gland Tumours ◽  
Adenoid Cystic ◽  
Solitary Liver ◽  
Solitary Metastases

Adenoid cystic carcinoma (ACC) is a relatively rare tumour of the salivary glands, accounting for approximately 5%–10% of all salivary gland tumours. An important feature of ACCs is the long clinical course with a high rate of distant metastases. The preferential sites of metastases are the lung and bone, followed by the brain and liver. Most liver metastases are derived from nonparotid ACCs, and the presentation is often related to local recurrence or metastases to other organs. Solitary metastases to the liver are rare and optimal management is unknown. We present the case of a metastatic ACC to the liver with primary disease presentation at a young age. We discuss our management and other potential treatment modalities.

scholarly journals Definitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma: a preliminary report

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jian Chen ◽  
Jingfang Mao ◽  
Ningyi Ma ◽  
Kai-Liang Wu ◽  
Jiade Lu ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Group Performance ◽  
Primary Tumour ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Tumour Response ◽  
Carbon Ion Radiotherapy ◽  
Rare Tumour ◽  
Carbon Ion ◽  
Adenoid Cystic

Abstract Background Tracheobronchial adenoid cystic carcinoma (TACC) is a rare tumour. About one-third of patients miss their chance of surgery or complete resection as it is mostly detected in the advanced stage; hence, photon radiotherapy (RT) is used. However, the outcomes of photon RT remain unsatisfactory. Carbon ion radiotherapy (CIRT) is thought to improve the therapeutic gain ratio; however, the outcomes of CIRT in TACC are unclear. Therefore, we aimed to assess the effects and toxicities of CIRT in patients with TACC. Methods The inclusion criteria were as follows: 1) age 18–80 years; 2) Eastern Cooperative Oncology Group Performance Status 0–2; 3) histologically confirmed TACC; 4) stage III–IV disease; 5) visible primary tumour; and 6) no previous RT history. The planned prescription doses of CIRT were 66–72.6 GyE/22–23 fractions. The rates of overall survival (OS), local control (LC), and progression-free survival (PFS) were calculated using the Kaplan-Meier method. Treatment-induced toxicities and tumour response were scored according to the Common Terminology Criteria for Adverse Events and Response Evaluation Criteria in Solid Tumors, respectively. Results Eighteen patients with a median age of 48 (range 30–73) years were enrolled. The median follow-up time was 20.7 (range 5.8–44.1) months. The overall response rate was 88.2%. Five patients developed lung metastasis after 12.2–41.0 months and one of them experienced local recurrence at 31.9 months after CIRT. The rates of 2-year OS, LC, and PFS were 100, 100, and 61.4%, respectively. Except for one patient who experienced grade 4 tracheal stenosis, which was relieved after stent implantation, no other ≥3 grade toxicities were observed. Conclusions CIRT might be safe and effective in the management of TACC based on a short observation period. Further studies with more cases and longer observation are warranted.

Treatment outcomes of recurrent and metastatic adenoid cystic carcinoma: A retrospective analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18056-e18056
Author(s):  
Julie Elaine McGrath ◽  
Punita Grover ◽  
Joanne Xiu ◽  
Chadi Nabhan ◽  
Jennifer Hsing Choe ◽  
...  
Keyword(s):  
Overall Survival ◽  
Adenoid Cystic Carcinoma ◽  
Real World ◽  
Kinase Inhibitors ◽  
Checkpoint Inhibitors ◽  
Predictive Biomarkers ◽  
High Rate ◽  
Entire Cohort ◽  
Adenoid Cystic ◽  
Significant Difference

e18056 Background: Adenoid cystic carcinoma (ACC) is a rare malignancy of glandular tissue with a high rate of local recurrence and metastatic disease. Despite being regarded as an indolent disease, the clinical course of recurrent and metastatic ACC (R/M ACC) is highly variable. Responses to chemotherapy (chemo) are uniformly poor. Several multi-targeted tyrosine-kinase inhibitors (mTKIs), EGFR inhibitors (EGFRi) and other targeted agents have been studied in single-arm early phase trials with response rates ranging from 0-16% and progression free survival ranging from 2.5-17 months. However, there have been no comparative clinical trials and it is not known if one treatment strategy is superior. We undertook this retrospective study to assess the real-world clinical outcomes in patients with adenoid cystic carcinoma using the Caris Life Sciences database. Methods: Real world overall survival (rwOS) for cases of ACC was obtained from insurance claims data and Kaplan-Meier estimates were calculated from the date of collection to the date of last contact. Cases were divided into subgroups based on treatment received – chemo (including platinum agents, taxanes, 5FU, topoisomerase inhibitors, anthracyclines), EGFRi (cetuximab, erlotinib, lapatinib), mTKIs (pazopanib, axitinib, sunitinib, cabozantinib, lenvatinib, sorafenib) and immune checkpoint inhibitors (ICIs) (atezolizumab, ipilimumab, pembrolizumab, nivolumab). Results: 368 patients (pts) were identified with ACC, 16 were locally recurrent and 216 tumors were taken from metastatic sites. 50 pts received chemo, 6 were treated with EGFRi and 15 with mTKIs. Pts who received combination EGFRi and chemo or mTKI and chemo were excluded. The median overall survival (mOS) all patients with metastatic ACC was 2.8 years (yrs). The mOS of pts with R/M ACC was 3 yrs for chemo, 2.9 yrs for EGFRi and 1.5 yrs for mTKIs. There was no significance in mOS between chemo vs mTKIs (HR 0.85, 95% CI 0.3 - 2, p = 0.72) and chemo vs EGFRi (HR = 0.88, 95% CI 0.3 - 2.5, p = 0.78). We further compared the outcomes of those treated with EGFRi (n = 8) with mTKIs (n = 19) in the entire cohort. For most pts, these agents were given as front line therapy. 25% (2/8) of patients had received treatment prior to EGFRi and 20% (4/9) prior to mTKIs (p = 1). There was no significant difference in mOS with HR 0.6 (95% CI 0.16 - 2.6), p = 0.6. We also compared the mOS of patients who received ICIs (n = 22) with those who did not (n = 346) but there was no significant difference (mOS 3.19 vs 3.17 yrs respectively, HR 0.87, 95% CI 0.47- 1.61, p = 0.65). Conclusions: There was no significant difference in the mOS between pts with R/M ACC who were treated with chemo, EGFRi or TKIs and in those who received ICIs compared to those who did not in our limited patient population. This highlights the need for predictive biomarkers for better patient selection with the goal of personalizing treatment strategies for this disease.

Two malignant salivary gland tumours of different type in one patient

1994 ◽  
Vol 108 (9) ◽  
pp. 798-800 ◽  
Author(s):  
A. Hosni ◽  
C. Fisher ◽  
P. Rhŷ-Evans
Keyword(s):  
Salivary Gland ◽  
Parotid Gland ◽  
Adenoid Cystic Carcinoma ◽  
Salivary Glands ◽  
Submandibular Gland ◽  
Histological Type ◽  
Salivary Gland Tumours ◽  
Adenoid Cystic ◽  
The Right ◽  
Left Parotid Gland

AbstractThe synchronous or metachronous occurrence of two tumours of the salivary glands in one patient is rare. These are mainly benign and of the same histological type. Here we report a 56-year-old man who developed a mucoepidermoid tumour of the left parotid gland four years after diagnosis of adenoid cystic carcinoma of the right submandibular gland. This combination of neoplasms has not to our knowledge been reported before.

Adenoid cystic carcinoma of the salivary glands: Clinicopathological survey of 51 patients

1989 ◽  
Vol 103 (7) ◽  
pp. 675-679 ◽  
Author(s):  
V. N. Koka ◽  
R. M. Tiwari ◽  
I. van der Waal ◽  
G. B. Snow ◽  
J. Nauta ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Radical Surgery ◽  
Neck Region ◽  
Distant Metastases ◽  
Head And Neck Region ◽  
Histological Features ◽  
Adenoid Cystic ◽  
Small Series ◽  
Clinicopathological Study

AbstractA clinicopathological study of 51 cases of adenoid cystic carcinoma in the head and neck region seen over a period of 20 years is presented. The correlation between various histological features and their impact on the results is attempted. Longterm results with respect to loco-regional recurrences, distant metastases and survival with various modalities of therapy are presented. Although this is a small series, radical surgery in keeping with the aim of avoiding undue mutilation, thus preserving the quality of life, followed by a full course of radiotherapy has been the mainstay of treatment and the results here presented justify this approach.

Adenoid Cystic Carcinoma of the Base of the Tongue

2001 ◽  
Vol 110 (3) ◽  
pp. 248-253 ◽  
Author(s):  
Ali Namazie ◽  
Sassan Alavi ◽  
Thomas C. Calcaterra ◽  
Elliot Abemayor ◽  
Keith E. Blackwell
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Postoperative Radiotherapy ◽  
Survival Rates ◽  
Disease Process ◽  
Distant Metastases ◽  
Swallowing Function ◽  
Term Survival ◽  
Adenoid Cystic ◽  
Regional Metastases ◽  
Carcinoma Of The Tongue

A retrospective review of 14 patients with adenoid cystic carcinoma of the tongue treated between 1955 and 1997 was performed. Treatment consisted of surgery (n = 2), radiotherapy (n = 2), chemotherapy (n = 1), or combination therapy (n = 9). The 2-, 5-, and 10-year absolute survival rates were 92%, 79%, and 63%, respectively. Seventy-five percent of the patients who died of cancer succumbed to distant metastases. However, long-term survival was common despite a high incidence of local and distant recurrence. The presence of positive surgical margins, the incidence of regional metastases, the incidence of perineural invasion, the initial stage of disease, and the eventual development of locoregional recurrence and distant metastases did not significantly alter the survival rate. Surgical extirpation combined with postoperative radiotherapy is advocated for the treatment of adenoid cystic carcinoma of the tongue. Given the indolent nature of this disease process, surgery should be directed toward conservation of speech and swallowing function.

Clinical and pathological studies on adenoid cystic carcinoma originating from the salivary gland. Recurrence and lymph node and distant metastases.

1995 ◽  
Vol 41 (1) ◽  
pp. 36-44
Author(s):  
Kazuo RYOKE ◽  
Satoshi KATAOKA ◽  
Satoshi KANO ◽  
Keisuke TAKAHASHI ◽  
Shinzo ISHIKURA ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Lymph Node ◽  
Adenoid Cystic Carcinoma ◽  
Distant Metastases ◽  
Adenoid Cystic

scholarly journals Adenoid cystic carcinoma of the breast: case report and review of literature

2012 ◽  
Vol 94 (4) ◽  
pp. e137-e138 ◽  
Author(s):  
R Veeratterapillay ◽  
S Veeratterapillay ◽  
E Ward ◽  
H Khout ◽  
T Fasih
Keyword(s):  
Case Report ◽  
Adenoid Cystic Carcinoma ◽  
Rare Condition ◽  
Good Prognosis ◽  
Treatment Modalities ◽  
Review Of Literature ◽  
Breast Lump ◽  
Carcinoma Of The Breast ◽  
Adenoid Cystic

We report the case of a patient who presented with a painful breast lump that turned out to be an adenoid cystic carcinoma of the breast. The literature is reviewed, highlighting the good prognosis associated with this rare condition and the current preferred treatment modalities.

Role of radiotherapy in adenoid cystic carcinoma of the head and neck

2009 ◽  
Vol 123 (10) ◽  
pp. 1137-1144 ◽  
Author(s):  
T A Iseli ◽  
L H Karnell ◽  
S M Graham ◽  
G F Funk ◽  
J M Buatti ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Distant Metastases ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Prognostic Features ◽  
Adenoid Cystic ◽  
Radiotherapy Alone ◽  
Local Recurrence Free Survival

AbstractThis study retrospectively reviewed 183 cases of adenoid cystic carcinoma treated over 40 years. The local recurrence free survival rate was 68.2 per cent at five years and 40.8 per cent at 10 years. At 10 years, local recurrence free survival was significantly worse following radiotherapy alone (0 per cent), compared with surgery alone (41.8 per cent, p = 0.004) or combined with post-operative radiotherapy (43.5 per cent, p = 0.001). Neither tumour stage three or four, perineural invasion, solid subtype nor involved margins predicted local recurrence. Treatment with radiotherapy alone resulted in worse survival than surgery alone (p = 0.002) or combined with post-operative radiotherapy (p = 0.001). Survival rates following local recurrence (n = 34) were higher following surgery (p = 0.006) but not significantly improved following radiotherapy (p = 0.139). Chemotherapy for distant metastases did not prolong survival (p = 0.747) but did result in improved eating and aesthetics scores, while decreasing overall physical health. These results indicate that surgery is preferable for primary and recurrent adenoid cystic carcinoma of the head and neck. The incidence of local recurrence following surgery and postoperative radiotherapy was similar to surgery alone cases although the latter had less adverse prognostic features. Contemporary chemotherapy may benefit quality of life but not survival in patients with distant metastases due to adenoid cystic carcinoma of the head and neck.

Septal, widely infiltrative and clinically occult adenoid cystic carcinoma of the parotid gland

1997 ◽  
Vol 111 (5) ◽  
pp. 491-492 ◽  
Author(s):  
A. Coup ◽  
J. M. S. Williamson ◽  
J. W. A. Curley
Keyword(s):  
Salivary Gland ◽  
Parotid Gland ◽  
Adenoid Cystic Carcinoma ◽  
Clinical Setting ◽  
Salivary Gland Tumours ◽  
Adenoid Cystic

AbstractMost salivary gland tumours present with an obvious mass and are usually diagnosed clinically. We present a case of occult adenoid cystic carcinoma of the parotid which, due to its peculiar septal pattern of growth and complicated clinical setting. defied diagnosis for several years.

Sign in / Sign up

Export Citation Format

Share Document